TY - JOUR A1 - Rauert-Wunderlich, Hilka A1 - Berberich, Ingolf A1 - Rosenwald, Andreas A1 - Rudelius, Martina T1 - CD40L mediated alternative NF kappa B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma JF - Cell Death & Disease N2 - Drug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF kappa B) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF kappa B signaling and illustrated the ability of CD40L to activate the alternative NF kappa B pathway in MCL. This activation leads to independency of classical NF kappa B signaling and results in resistance to BCR inhibitors. Therefore, ligands (such as CD40L) and their activation of the alternative NF kappa B pathway have a major impact on the drug response in MCL. Furthermore, this study indicates a protective role for cells expressing specific ligands as microenvironmental niches for MCL cells and underlines the significance of therapeutically targeting alternative NF kappa B signaling in MCL. KW - Bruton Tyrosine Kinase KW - Tumor Microenvironment KW - Targeted Therapies KW - Ibrutinib KW - Pathway KW - Malignancies KW - Activation KW - Ligand KW - Proliferation KW - PCI-32765 Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225027 IS - 9 ER - TY - JOUR A1 - Plötz, P.-A. A1 - Polyutov, S. P. A1 - Ivanov, S. D. A1 - Fennel, F. A1 - Wolter, S. A1 - Niehaus, T. A1 - Xie, Z. A1 - Lochbrunner, S. A1 - Würthner, Frank A1 - Kühn, O. T1 - Biphasic aggregation of a perylene bisimide dye identified by exciton-vibrational spectra JF - Physical Chemistry Chemical Physics N2 - The quantum efficiency of light emission is a crucial parameter of supramolecular aggregates that can be tuned by the molecular design of the monomeric species. Here, we report on a strong variation of the fluorescence quantum yield due to different phases of aggregation for the case of a perylene bisimide dye. In particular, a change of the dominant aggregation character from H- to J-type within the first aggregation steps is found, explaining the observed dramatic change in quantum yield. This behaviour is rationalised by means of a systematic study of the intermolecular potential energy surfaces using the time-dependent density functional based tight-binding (TD-DFTB) method. This provides a correlation between structural changes and a coupling strength and supports the notion of H- type stacked dimers and J-type stack-slipped dimers. The exciton-vibrational level structure is modelled by means of an excitonic dimer model including two effective vibrational modes per monomer. Calculated absorption and fluorescence spectra are found to be in reasonable agreement with experimental ones, thus supporting the conclusion on the aggregation behaviour. KW - Potential-energy curves KW - Simulations KW - Molecular-dynamics KW - Systems KW - Fluorescence KW - Sracking KW - Pathway KW - Dimers KW - State Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187387 VL - 18 IS - 36 ER - TY - JOUR A1 - Gowda, Madhu A1 - Godder, Kamar A1 - Kmieciak, Maciej A1 - Worschech, Andrea A1 - Ascierto, Maria-Libera A1 - Wang, Ena A1 - Francesco M., Marincola A1 - Manjili, Masoud H. T1 - Distinct signatures of the immune responses in low risk versus high risk neuroblastoma JF - Journal of Translational Medicine N2 - Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response. Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1 beta, a cytokines which is involved in the innate immune responses. Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1b induced expression of cytokines of the innate immune responses. Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients. KW - Neural precursor cells KW - Retinoic acid KW - Ifn-gamma KW - Progenitor cells KW - Breast-cancer KW - T-lymphocytes KW - IN-VIVO KW - Differentiation KW - Pathway KW - Activation KW - Neuroblastoma KW - innate immunity KW - adaptive immunity KW - prognostic biomarkers Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135147 VL - 9 IS - 170 ER - TY - JOUR A1 - Wedel, Steffen A1 - Hudak, Lukasz A1 - Seibel, Jens-Michael A1 - Makarevic, Jasmina A1 - Juengel, Eva A1 - Tsaur, Igor A1 - Waaga-Gasser, Ana A1 - Haferkamp, Axel A1 - Blaheta, Roman A. T1 - Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis JF - BMC Cancer N2 - Background: Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001, the dual EGFr and VGEFr tyrosine kinase inhibitor AEE788 and the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer growth and adhesion in vitro was investigated. Methods: PC-3, DU-145 and LNCaP cells were treated with RAD001, AEE788 or VPA or with a RAD-AEE-VPA combination. Tumor cell growth, cell cycle progression and cell cycle regulating proteins were then investigated by MTT-assay, flow cytometry and western blotting, respectively. Furthermore, tumor cell adhesion to vascular endothelium or to immobilized extracellular matrix proteins as well as migratory properties of the cells was evaluated, and integrin alpha and beta subtypes were analyzed. Finally, effects of drug treatment on cell signaling pathways were determined. Results: All drugs, separately applied, reduced tumor cell adhesion, migration and growth. A much stronger anticancer effect was evoked by the triple drug combination. Particularly, cdk1, 2 and 4 and cyclin B were reduced, whereas p27 was elevated. In addition, simultaneous application of RAD001, AEE788 and VPA altered the membranous, cytoplasmic and gene expression pattern of various integrin alpha and beta subtypes, reduced integrin-linked kinase (ILK) and deactivated focal adhesion kinase (FAK). Signaling analysis revealed that EGFr and the downstream target Akt, as well as p70S6k was distinctly modified in the presence of the drug combination. Conclusions: Simultaneous targeting of several key proteins in prostate cancer cells provides an advantage over targeting a single pathway. Since strong anti-tumor properties became evident with respect to cell growth and adhesion dynamics, the triple drug combination might provide progress in the treatment of advanced prostate cancer. KW - Growth-factor receptor KW - Mammalian target KW - Radical prostatectomy KW - Up-regulation KW - C-MYC KW - Pathway KW - Expression KW - Activation KW - Inhibition KW - Apoptosis Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141075 VL - 11 IS - 375 ER -